Welcome to our dedicated page for Arcus Bioscience news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Bioscience stock.
Arcus Biosciences, Inc. reports developments as a clinical-stage global biopharmaceutical company developing differentiated molecules and combination therapies for cancer and inflammatory and autoimmune diseases. Company news commonly covers quarterly financial results, pipeline updates, clinical program strategy, data presentations and changes in research priorities across its investigational portfolio.
Recurring updates focus on casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer, and earlier inflammation programs such as AB102, an MRGPRX2 antagonist. Arcus also issues routine corporate announcements on employment inducement grants, investor conference participation and collaboration-related developments.
Arcus Biosciences reported Q4 and full-year 2022 financial results, highlighting a net loss of $67 million for Q4 and $267 million for the full year. Revenues dropped to $34 million in Q4, down from $355 million in the previous year. The firm holds $1.1 billion in cash and equivalents, sufficient to fund operations into 2026. Domvanalimab, their lead molecule, has shown promising results in ongoing Phase 3 studies, particularly in non-small cell lung cancer (NSCLC), with median progression-free survival extending to 12 months. Updates on clinical studies and further data presentations are expected throughout 2023.
Arcus Biosciences (NYSE:RCUS) has granted stock options to three new employees, totaling 7,000 shares at an exercise price of $18.66, the closing price on February 23, 2023. Additionally, restricted stock units were awarded for 3,500 shares. These grants fall under the 2020 Inducement Plan approved in January 2020 and adhere to NYSE rules. Arcus is a clinical-stage biopharmaceutical firm focused on innovative cancer therapies, developing six investigational medicines targeting various biological pathways.
Arcus Biosciences (NYSE:RCUS) announced the granting of stock options and restricted stock units to eight new employees. A total of 31,600 shares were allocated at an exercise price of $20.68, based on the closing price on February 8, 2023. Additionally, 15,800 shares in restricted stock units were granted. These equity awards were issued under the Company’s 2020 Inducement Plan, approved in January 2020. This move aims to enhance recruitment and retention of talent in their ongoing efforts to develop innovative cancer therapies.
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company, announced participation in two virtual investor events in February 2023. The events include the SVB Securities Virtual Global Biopharma Conference on February 14 at 12:00 p.m. ET, and Citi’s 2023 Virtual Oncology Leadership Summit on February 21 at 1:00 p.m. ET. Both will feature fireside chats from the management team. Webcasts will be accessible through the “Investors & Media” section of the Arcus Biosciences website, with replays available post-event. The company is focused on developing innovative cancer therapies and has advanced six investigational medicines into clinical studies.
Arcus Biosciences (NYSE:RCUS) announced the granting of stock options and restricted stock units to ten new employees. The options allow the purchase of 44,300 shares at an exercise price of $22.02, the closing price on January 23, 2023. Additionally, 22,150 shares in restricted stock units were granted. These equity awards fall under the Company’s 2020 Inducement Plan, approved in January 2020. Arcus, founded in 2015, focuses on developing innovative cancer therapies, having advanced six investigational medicines into clinical studies targeting various cancer-related pathways.
Gilead Sciences (GILD) and Arcus Biosciences (RCUS) reported positive interim results from the ARC-7 study, a Phase 2 trial in patients with first-line metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression. Both doublet and triplet therapy arms containing domvanalimab showed a 35-45% reduction in the risk of progression or death compared to zimberelimab monotherapy, with median progression-free survival (PFS) of 12.0 months for the doublet and 10.9 months for the triplet. Results will be showcased on December 20 during the ASCO Monthly Plenary Series.
Gilead Sciences and Arcus Biosciences reported promising results from the ARC-7 Study, focusing on first-line, metastatic non-small cell lung cancer (NSCLC). The study demonstrated a 35-45% reduction in the risk of progression or death and a significant improvement in median progression-free survival (PFS) with the combination therapies compared to zimberelimab monotherapy. The objective response rates showed a positive trend, with the doublet and triplet arms showing 41% and 40%, respectively. Further detailed results will be presented on December 20.
Arcus Biosciences announced the grant of stock options and restricted stock units to five new employees. A total of 8,200 shares can be purchased at an exercise price of $31.00, the closing price on December 8, 2022. Additionally, 4,100 restricted stock units were granted. These awards are part of the company’s 2020 Inducement Plan, approved in January 2020. Arcus Biosciences focuses on developing innovative cancer therapies and has expedited six investigational medicines into clinical studies.
Gilead Sciences (GILD) and Arcus Biosciences (RCUS) announced positive results from the fourth interim analysis of the Phase 2 ARC-7 study for first-line metastatic non-small cell lung cancer (NSCLC). The analysis, conducted with a data cutoff on August 31, 2022, included 150 patients and demonstrated that both domvanalimab combinations significantly outperformed zimberelimab monotherapy across multiple efficacy measures, including progression-free survival (PFS). Results will be presented at the ASCO Monthly Plenary Series on December 20, 2022.
Gilead Sciences and Arcus Biosciences announced promising results from the fourth interim analysis of the Phase 2 ARC-7 study for first-line NSCLC patients. The study evaluates the effects of domvanalimab (anti-TIGIT) in combination with zimberelimab (anti-PD-1) versus zimberelimab alone. Results indicate significant clinical benefits across key efficacy measures, including progression-free survival (PFS). No unexpected safety issues were noted. Full results will be presented on December 20, 2022, at the ASCO Monthly Plenary Series.